Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

SAN DIEGO, Nov. 3, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company's financial results for the quarter ended September 30, 2011.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Optimer reported total revenues for the third quarter of 2011 of $11.1 million, compared $669,000 for the third quarter in 2010. This includes net product sales of $10.6 million recognized from the sale of DIFICID™. Optimer recognizes product sales of DIFICID upon delivery of product to its wholesalers.

  • For the quarter ended September 30, 2011, the $10.6 million in net sales to wholesalers reflected a total of 4,335 DIFICID treatments
  • 2,505 DIFICID treatments were shipped from wholesalers to hospitals, retail pharmacies and long-term care facilities in the quarter ended September 30, 2011
  • 535 hospitals had ordered DIFICID as of September 30, 2011
  • 304 hospitals had placed DIFICID on formulary, and 346 hospital formulary reviews were pending as of October 21, 2011.

  • "In only a few months since our first DIFICID sale on July 19th we've seen significant interest in DIFICID converting into uptake and adoption. We reported $10.6 million in sales to our wholesalers in the third quarter, and we expect continued strong uptake as the launch progresses," said Pedro Lichtinger, President and CEO of Optimer. "This confirms our belief that DIFICID meets the need for a Clostridium difficile-associated diarrhea treatment addressing the problem of recurrence by providing a sustained clinical response. As the medical community becomes more familiar with and recognizes the value of DIFICID, we anticipate that adoption will continue."Optimer reported a net loss for the third quarter of 2011 of $26.4 million, or ($0.57) 
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
    2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
    3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
    4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
    5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
    6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
    7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
    8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
    9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
    10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
    11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/5/2015)... May 05, 2015 VetStem Biopharma, ... Animal Health, Jeffrey Schaffer, DVM, as Director of ... 15 years of experience in the veterinary regenerative ... addition to our veterinarian lead organization”. Dr. ... “Dr. Schaffer will be responsible for all technical ...
    (Date:5/5/2015)... May 05, 2015 Research and Markets ... the addition of the "Separation Systems ... offering. Macromolecules which include protein, ... or are broken into smaller molecules, during ... separation requires various advanced systems like centrifugation, ...
    (Date:5/5/2015)... TEL AVIV, Israel , May 5, 2015 ... that the Company was approved to continue trading ... companies. OTCQB Marketplace allows for ... an electronic broker-dealers. Investors can have real-time quotes ... The OTCQB Marketplace includes ...
    (Date:5/5/2015)... , May 5, 2015  Renova™ Therapeutics, ... congestive heart failure and other chronic diseases, has ... independent analysis designed to reflect the healthcare patterns ... This model will be used to characterize the ... could have on those groups of patients and ...
    Breaking Biology Technology:Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3
    (Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
    (Date:4/2/2015)... 2, 2015 At its 2015 ACMG Annual ... , the American College of Medical Genetics and ... to its Board.  Members of the ACMG Board of ... forming and advancing its policies and programs. ACMG is ... "It,s an eventful time in medical genetics and ...
    (Date:4/1/2015)... --  Medisafe ™, the leading global medication management platform ... and Android smartphones and tablets, announces today ... to allow patients to track and correlate their adherence ... will be able to visualize in real-time how taking ... as glucose levels and blood pressure. "Patients ...
    Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
    ... is a delicacy costing up to SEK 8,000 a kilo ... has discovered that this tasty fungus also grows wild in Sweden. ... Sweden, and definitely in Japan once these discoveries become known there," ... is a family of many different species of fungi. One ...
    ... available in <A HREF=",http://chinese.eurekalert.org/zh/emb_releases/2010-06/du-wmi062410.php,">Chinese . DURHAM, ... far greater than those found in seawater, it,s the ... up posing a more serious health threat to humans ... University researchers, is in the seawater itself. The ...
    ... Beijing, June 27th, 2010 The Elsevier Foundation, ... twelve talented women scientists from Africa, the Middle East, ... excellence. The announcement was made at the Third World ... and International Conference, Women Scientists in a Changing World, ...
    Cached Biology News:Japanese gourmet mushroom found in Sweden 2Japanese gourmet mushroom found in Sweden 3Why mercury is more dangerous in oceans 212 women scientists announced as winners of Elsevier Foundation TWOWS Awards 2
    ... S2 cells are used for heterologous protein ... (DES). The S2 cell line was derived ... hours old) Drosophila melanogaster embryos (1). ... room temperature without CO2 and is easily adapted ...
    ... syringe pump series combines Harvard Apparatuss best pump ... a wide range of configuration options. A lookup ... of syringes from all the major manufacturers. A ... the pertinent information from across the lab. All ...
    ... For our novel expression vectors, we in-troduced ... dual controls: (i) at tran-scriptional level at the ... replication level by amplifying the plasmid copy number, ... is that it retains practically all of the ...
    ... This CLS number is a new ... product number. If showing no availability yet, ... (C6421) or contact customer service for assistance. ... Comp Dim: surface area 21 cm ...
    Biology Products: